$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Primary ciliary dyskinesia (PCD) is a rare, hereditary genetic disorder, which causes disturbances in the movement of beating cilia. If undiagnosed, it leads to severe lung damage in later life due to severe impairment of MCC. In the past, its prevalence has been estimated to be in the range of 1:4,000 to 50,000. Due to steadily improving diagnostics and a growing awareness of the condition, updates on the prevalence of PCD suggest that it might be much more common and probably in the range of 1:4,000 to 20,000 instead1,2. However, patients with PCD are still underdiagnosed or diagnosed too late1,3. Therefore, infants with either congenital situs inversus and/or heterotaxy or perinatal rhinorrhea, neonatal respiratory distress, a blocked nose, and feeding difficulties should be suspects for PCD. In later life, chronic otitis, recurrent pneumonia, rhinosinusitis, and a chronic, typical wet cough due to impaired MCC are the hallmark symptoms of PCD, which in combination with bronchiectasis and impaired lung function, continue into adulthood2.
Patients suspected of having PCD can be diagnosed by using different diagnostic tools. TEM has been considered the gold standard for first-line diagnostics in the past. However, up to 30% of PCD cases do not show abnormal ultrastructure1,3,4,5,6, demanding a different diagnostic approach. Therefore, a growing number of centers and the guidelines of the European Respiratory Society (ERS) suggest a combination of nasal nitric oxide (nNO) and HSVMA as first-line diagnostics1,7,9,10. HSVMA and nNO are also the most cost-effective options in identifying a patient with PCD11. However, even if genetic testing were included in the diagnostics, it must be kept in mind that there is currently no stand-alone test or combination of tests that can exclude PCD with 100% certainty8,9,10.
Out of the available diagnostic options, HSVMA is the only test that focuses on living, cilia-coated respiratory cells and evaluates ciliary beat pattern (CBP) and ciliary beat frequency (CBF). In contrast to TEM, the results of HSVMA are available quickly, usually on the day of testing, whereas results of TEM might arrive months after the specimen has been taken. HSVMA can be applied for all age groups, whereas nNO demands a high degree of compliance; attempts to use it under the age of 5 years are usually unsuccessful10. In experienced hands, HSVMA has excellent sensitivity and specificity to diagnose PCD at 100% and 96%, respectively12.
This paper describes the step-by-step procedure to perform HSVMA, including the harvesting of cilia-coated respiratory cells from the inferior turbinate of the nose, the preservation of harvested cells in a cell-nourishing medium for transport to the site of investigation, and the process of microscopic video analysis to determine CBF and CBP. Additionally, some video clips from patients are shown, comparing normal CBPs and CBFs with abnormal cilia function (Video 3, Video 4, Video 5, Video 6, Video 7, and Video 8).